NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT01743131 2025-12-11Abatacept as GVHD Prophylaxis Phase 2Boston Children's HospitalPhase 2 Completed186 enrolled 14 charts 1 FDA
NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 1 FDA
NCT02953678 2021-11-24A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Incyte CorporationPhase 2 Completed71 enrolled 24 charts 1 FDA
NCT02195869 2019-07-11Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseasePharmacyclics LLC.Phase 1/2 Completed45 enrolled 13 charts 1 FDA